RG Biopharma is a San Diego-based company founded in 2010 for the purpose of developing novel approaches to cancer screening and treatment.
We are developing clinical tests for cancer therapy selection based on a unique molecular biomarker that identifies tumors most likely to respond to the camptothecin–derived chemotherapeutic drugs, irinotecan and topotecan. This important class of chemotherapeutics is used for the treatment of colon cancer, lung cancer, and ovarian cancer. This research has been funded by the National Institutes of Health/ National Cancer Institute and has led to RG Biopharma’s patented technology for therapy selection.
Our technology addresses an urgent and unmet need for therapy selection tools. Camptothecin-based chemotherapeutic drugs are not effective in all patients and no diagnostic tests are currently available for predicting responses. By providing a tool for therapy selection, RG Biopharma’s technology could save lives and improve treatment outcomes by ensuring that each patient initially receives the treatment best suited to his or her individual tumor phenotype.
San Diego, CA